Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study
Becker, Richard C × Moliterno, David J Jennings, Lisa K Pieper, Karen S Pei, Jinglan Niederman, Alan Ziada, Khaled M Berman, Gail Strony, John Joseph, Diane Mahaffey, Kenneth W Van de Werf, Frans Veltri, Enrico Harrington, Robert A #
Elsevier science inc
Lancet vol:373 issue:9667 pages:919-928
Background An antithrombotic drug is needed that safely reduces cardiovascular events in patients undergoing percutaneous coronary intervention (PCI). We therefore assessed the tolerability and safety of SCH 530348-an oral platelet protease-activated receptor-1 antagonist.